NVIDIA’S FUTURE, QUANTUM’S PROFITABILITY & A NUCLEAR PULLBACK — A NUCLEAR PHYSICIST REVEALS THE ROADMAP TO MASSIVE OPPORTUNITIES

By Nigam Arora & Dr. Natasha Arora

The excitement around technology is not slowing down — it may continue until 2030 and beyond. However, investors should manage expectations.

Nigam Arora, a nuclear physicist, explains why Nvidia (NVDA) remains well positioned but cautions that the explosive returns of 2024 are unlikely to repeat. Meanwhile, quantum technology is proving its potential for profitability, with IBM (IBM) leading the way, though margins will take time to improve.

Nuclear energy is expected to play a critical role in powering AI, but investors should be aware of a possible 50% or greater pullback within the next two years.

For a deeper dive into these insights, watch the full interview with Nigam Arora on Schwab Network.

Please click here to start a 30 day free trial.  Your credit card is not charged during the trial period.

Markets can generate substantial wealth for knowledgeable investors. NOW YOU TOO CAN ALSO SPECTACULARLY SUCCEED AT MEETING YOUR GOALS WITH THE HELP OF THE ARORA REPORT. You are receiving less than 2% of the content from our paid services. …TO RECEIVE REMAINING 98% INCLUDING MANY ATTRACTIVE INVESTMENT OPPORTUNITIES, TAKE A FREE
TRIAL TO PAID SERVICES.

Please click here to take advantage of a FREE 30 day trial.

Nigam Arora

Nigam Arora is known for his accurate stock market calls. Nigam is a distinguished master of the macro. He is a popular columnist with over 100 million page views, an engineer, and nuclear physicist by background. Nigam has founded two Inc. 500 fastest growing companies and has been involved in over 50 entrepreneurial ventures. He is the developer of Theory ZYX of Successful Change Management and is the author of the book on Theory ZYX, as well as the developer of the ZYX Change Method for Investing.

See also  HERE IS HOW TO LOOK AHEAD IN THIS MARKET, CHINA DASHES STOCK MARKET BULLS HOPIUM, BOND CANARY SICK

Dr. Natasha Arora

Dr. Natasha Arora has significant expertise in investment analysis especially biotech, healthcare, and technology. Natasha is a graduate of Harvard Medical School followed by a postdoc at MIT. She has published several peer reviewed research papers in top science journals.